# Influence analyses of "designs" for evaluating inconsistency in network meta-analysis

Kotaro Sasaki, MPH The Graduate Institute for Advanced Studies, The Graduate University for Advanced Studies (SOKENDAI), Tokyo, Japan Human Biology Integration Foundation, Deep Human Biology Learning, Eisai Co. Ltd., Tokyo, Japan ORCID: <u>https://orcid.org/0009-0007-3081-9438</u> Hisashi Noma, PhD\*

Department of Interdisciplinary Statistical Mathematics, The Institute of Statistical Mathematics, Tokyo, Japan The Graduate Institute for Advanced Studies, The Graduate University for Advanced Studies (SOKENDAI), Tokyo, Japan ORCID: http://orcid.org/0000-0002-2520-9949

\*Corresponding author: Hisashi Noma

Department of Interdisciplinary Statistical Mathematics

The Institute of Statistical Mathematics

10-3 Midori-cho, Tachikawa, Tokyo 190-8562, Japan

TEL: +81-50-5533-8440

e-mail: noma@ism.ac.jp

#### Abstract

Network meta-analysis is an evidence synthesis method for comparative effectiveness analyses of multiple available treatments. To justify evidence synthesis, consistency is a relevant assumption; however, existing methods founded on statistical testing possibly have substantial limitations of statistical powers or several drawbacks in treating multiarm studies. Besides, inconsistency is theoretically explained as design-by-treatment interactions, and the primary purpose of these analyses is prioritizing "designs" for further investigations to explore sources of biases and irregular issues that might influence the overall results. In this article, we propose an alternative framework for inconsistency evaluations using influence diagnostic methods that enable quantitative evaluations of the influences of individual designs to the overall results. We provide four new methods to quantify the influences of individual designs through a "leave-one-design-out" analysis framework. We also propose a simple summary measure, the O-value, for prioritizing designs and interpreting these influential analyses straightforwardly. Furthermore, we propose another testing approach based on the leave-one-design-out analysis framework. By applying the new methods to a network meta-analysis of antihypertensive drugs, we demonstrate the new methods located potential sources of inconsistency accurately. The proposed methods provide new insights into alternatives to existing test-based methods, especially quantifications of influences of individual designs on the overall network metaanalysis results.

Keywords: network meta-analysis, inconsistency, design-by-treatment interaction, influence diagnostics, bootstrap.

#### 1. Introduction

Network meta-analysis is an evidence synthesis method for comparative effectiveness analyses of multiple available treatments via pooling evidence from direct and indirect comparisons <sup>1,2</sup>. To justify evidence synthesis in network meta-analysis, consistency is a relevant assumption. Conventionally, "consistency" refers to the agreement between evidence of direct and indirect comparisons <sup>1</sup>; however, Higgins et al. <sup>3</sup> showed that this concept is rigorously explained as design-by-treatment interactions on the network, where "design" refers to the combination of treatments compared in the corresponding studies in this case. Also, "inconsistency" refers to a disagreement of treatment effects across different combinations of treatment comparisons on the network, and various statistical tools to evaluate it have been developed <sup>3-7</sup>.

Currently, most of the inconsistency evaluation methods are founded on statistical testing and have substantial limitations or drawbacks for detecting inconsistency accurately. Representative testing approaches included local and global inconsistency tests <sup>3,4</sup>. Local testing evaluates the concordance of effect sizes on a specific triangle loop of treatments. The main drawback of local methods is that there is no unique way to handle multi-arm studies ( $\geq$ 3 arms), which can lead to different estimates and conclusions <sup>8</sup>. Also, the statistical power to detect loop inconsistency is limited because limited numbers of studies are involved on individual triangles in practice <sup>9,10</sup>. On the other hand, the global inconsistency test evaluates the inconsistency on an entire network (i.e., it tests the design-by-treatment interactions on the network) <sup>3</sup>. This approach enables the involvement of multi-arm studies validly and utilizes all statistical information on a network to detect inconsistency. However, this approach also has limited statistical power in practice because most individual designs involve only a few studies (i.e., the interaction test is founded on the partially "sparse" nature of the dataset) <sup>11</sup>. Also, even if

inconsistency is detected, this testing method does not provide precise information about where the effect modifications exist. Other test-based inconsistency evaluation methods have similar drawbacks, especially statistical-power limitations due to the sparsity of the dataset. However, the primary purpose of the inconsistency evaluations is not to provide deterministic conclusions. The main purpose is to identify possible sources of biases or irregular problems on the network from the perspective of the discordances of effect sizes among different combinations of compared treatments. After checking the results of the inconsistency tests, we usually conduct further investigations for clinical or methodological factors that possibly influence the design-by-treatment interactions. Given the aforementioned issues, the testing approaches might not be suitable for these analyses; alternative methodological frameworks that enable prioritizations of further investigations and uncertainty evaluations might be useful in practice.

In this article, we propose new methods to prioritize study designs that indicate possible design-by-treatment interactions for further investigations as an alternative framework to assess inconsistency of network meta-analysis. In particular, we adopt the influence diagnostics framework and provide new methods to assess the influence of the corresponding design on the basis of how it changes the overall results of the network meta-analysis via leave-one-design-out analysis. We also provide quantification methods of uncertainty for the influence measures; these methods enable quantitative statistical evaluations of the certainty of the change in the overall results. The proposed methods have advantages in prioritizing individual designs and quantifying their influences that are suitable as preliminary analyses for further investigations. Also, these methods can handle multi-arm studies simply and directly identify the sources of inconsistency in practice. We illustrate the effectiveness of these new methods by applying them to a network meta-analysis of antihypertensive drugs <sup>12</sup>.

#### 2. Models and inference methods for network meta-analysis

We consider the contrast-based approach for network meta-analysis, that models relative treatment effect measures as multivariate outcomes <sup>3,11</sup>. Suppose that *N* studies are involved and that p + 1 treatments are compared. Let  $Y_{ij}$  denote an estimate of the treatment effect for treatment *j* compared with a reference treatment (e.g., placebo) in study i (i = 1, 2, ..., N; j = 1, 2, ..., p) (e.g., log odds-ratio and mean difference). Also, let  $Y_i = (Y_{i1}, Y_{i2}, ..., Y_{ip})^T$  denote the multivariate outcome. The multivariate statistical model for contrast-based network meta-analysis is given as

$$Y_i \sim \text{MVN}(\boldsymbol{\theta}_i, \boldsymbol{S}_i) \tag{1}$$

where  $S_i$  (a  $p \times p$  matrix) denotes the within-study covariance matrix,

$$\boldsymbol{S}_{i} = \begin{pmatrix} s_{i1}^{2} & \rho_{i12}s_{i1}s_{i2} & \cdots & \rho_{i1p}s_{i1}s_{ip} \\ \rho_{i21}s_{i2}s_{i1} & s_{i2}^{2} & \cdots & \rho_{i2p}s_{i2}s_{ip} \\ \vdots & \vdots & \ddots & \vdots \\ \rho_{ip1}s_{ip}s_{i1} & \rho_{ip2}s_{ip}s_{i2} & \cdots & s_{ip}^{2} \end{pmatrix}$$

which is usually assumed to be known and fixed to its valid estimate <sup>13</sup>. Also,  $\boldsymbol{\theta}_i$  is the true underlying effects for the *i*th study:  $\boldsymbol{\theta}_i = (\theta_{i1}, \theta_{i2}, ..., \theta_{ip})^T$ . When a study does not include a reference treatment, the data augmentation approach can be used, where quasi-small data are added into the reference arm (e.g., 0.001 events for 0.01 patients) <sup>11</sup>. Note that the choice of reference category does not affect the estimates of treatment effects in the data augmentation approach.

Further, we adopt the random-effects model to address between-studies heterogeneity,

$$\boldsymbol{\theta}_{i} \sim \text{MVN}(\boldsymbol{\mu}, \boldsymbol{\Sigma})$$

where  $\boldsymbol{\mu} = (\mu_1, \mu_2, ..., \mu_p)^T$  denotes the average treatment effect parameters and  $\boldsymbol{\Sigma}$  is the between-studies covariance matrix,

$$\boldsymbol{\Sigma} = \begin{pmatrix} \tau_1^2 & \kappa_{12}\tau_1\tau_2 & \cdots & \kappa_{1p}\tau_1\tau_p \\ \kappa_{21}\tau_2\tau_1 & \tau_2^2 & \cdots & \kappa_{2p}\tau_2\tau_p \\ \vdots & \vdots & \ddots & \vdots \\ \kappa_{p1}\tau_p\tau_1 & \kappa_{p2}\tau_p\tau_2 & \cdots & \tau_p^2 \end{pmatrix}$$

Because there are rarely sufficient studies available for all of the variance–covariance parameters in  $\Sigma$  to be identified, the equal variance assumption is adopted in most cases  $(\tau^2 = \tau_1^2 = \tau_2^2 = \cdots = \tau_p^2)^{6,14}$ . We also consistently adopt this assumption in the present study. Under the equal variance assumption, all pairwise correlation coefficients  $\kappa_{ij}$ s should be equal to 0.5 because of the consistency assumption <sup>15</sup>. Also, let  $W_i = (S_i + \Sigma)^{-1}$  denote the inverse of the marginal covariance matrix of  $Y_i$ . When  $\tau^2 = 0$ , this model reduces to the fixed-effect model <sup>16</sup>.

For parameter estimation, the restricted maximum likelihood (REML) estimation is widely adopted. The REML estimator  $(\hat{\mu}, \hat{\Sigma})$  is given through maximation of the log-restricted likelihood function,

$$\ell(\boldsymbol{\mu}, \boldsymbol{\Sigma}) \propto \sum_{i=1}^{N} \left\{ \log \left\{ \det \left( \boldsymbol{W}_{i}^{-1} \right) \right\} + (\boldsymbol{Y}_{i} - \boldsymbol{\mu})^{T} \boldsymbol{W}_{i} (\boldsymbol{Y}_{i} - \boldsymbol{\mu}) \right\} + \log \left\{ \det \left( \sum_{i=1}^{N} \boldsymbol{W}_{i} \right) \right\}$$

The covariance matrix estimator of  $\hat{\mu}$  is given as  $\hat{V}[\hat{\mu}] = (\sum_{i=1}^{N} \widehat{W}_i)^{-1}$ , where  $\widehat{W}_i = (S_i + \hat{\Sigma})^{-1}$ . Because most individual clinical trials involve only two to four arms, some elements of  $Y_i$  are often undefined and regarded as missing. In such cases, we replace  $Y_i$  and  $S_i$  with their subvectors and submatrices in the estimating functions <sup>13</sup>. The Wald-type tests and confidence intervals for  $\mu$  are constructed by the asymptotic normality of the REML estimator <sup>16</sup>. Several other alternative effective inference methods involving the higher-order asymptotic approximation are available for this multivariate random-effects model <sup>14,16</sup>, and the following discussions can be adapted to the alternative inference methods.

#### 3. Influence diagnostics of "designs"

In assessing the inconsistency of network meta-analysis, we consider prioritizing the study designs that indicate possible design-by-treatment interactions for further investigations. The key idea is that the specific designs that researchers should carefully treat in the primary analysis will have particularly strong influences on the overall results. Even if the inconsistency tests are significant, if the corresponding designs only weakly influence the overall results, they will not be important concerns in interpreting evidence of the network meta-analysis. Therefore, we propose adopting the influence diagnostics framework to quantitatively assess, via leave-one-design-out analysis, the influences of individual study designs on the basis of how they change the overall results of the network meta-analysis. Influence diagnostic methods for individual studies have been well established <sup>17-20</sup>; however, our concern is assessing the influences of "subsets of studies with the same designs." In this section, we provide four effective methods for evaluating the influence diagnostics of designs.

#### 3.1 Averaged studentized residual

We first propose an inconsistency diagnostic measure based on conventional residualbased statistics <sup>21</sup>. The studentized residual standardized by the standard error is one of the most commonly used measures to assess the influences of individual subjects <sup>17-21</sup>. However, in this case, we consider assessing the influence of a set of studies with the same design, possibly involving multiple studies; thus, the conventional studentized residual cannot be straightforwardly adapted. To quantify the influences of multiple studies simultaneously, we propose using the "averaged" studentized residual.

Let *D* denote the total number of designs on the network, and  $T_d$  denote an index set of studies with design d (d = 1, ..., D). We further denote ( $\hat{\mu}^{(-T_d)}, \hat{\Sigma}^{(-T_d)}$ ) as the REML estimator for the leave-one-design-out dataset that excludes the corresponding studies with the *d*th design, and  $\widehat{W}_{i}^{(-T_{d})} = (S_{i} + \widehat{\Sigma}^{(-T_{d})})^{-1}$ . We then first define the multivariate version of a studentized residual for the *i*th study as a quadratic form scaled by the number of comparisons  $p_{i}$  (i = 1, ..., N):

$$\xi_i = \frac{1}{p_i} \left( \boldsymbol{Y}_i - \hat{\boldsymbol{\mu}}^{(-T_d)} \right)^T \hat{\boldsymbol{V}} \left[ \boldsymbol{Y}_i - \hat{\boldsymbol{\mu}}^{(-T_d)} \right]^{-1} \left( \boldsymbol{Y}_i - \hat{\boldsymbol{\mu}}^{(-T_d)} \right)$$

where  $\widehat{V}[Y_i - \widehat{\mu}^{(-T_d)}] = (\widehat{W}_i^{(-T_d)})^{-1} + (\sum_{k \in (-T_d)} \widehat{W}_k^{(-T_d)})^{-1}$ . Note that, in the definition of  $\xi_i$ , we should set the reference treatment to one of the involved treatment arms in the *i*th study (the reference should be switched if the reference treatment is not involved) to avoid computational irregularities. We thereafter define the averaged studentized residual for the *d*th design as the mean of  $\xi_i$  among the studies with design *d*:

$$\Psi_d = \frac{1}{N_d} \sum_{i \in T_d} \xi_i$$

where  $N_d$  refers to the number of studies of design d. This influential measure is interpreted as a summary measure that assesses the overall influence of the studies with design d, and can be simply used as the conventional studentized residual. In general, a large value of  $\Psi_d$  indicates that a large difference exists between the estimates from studies with design d and the overall estimates from the other studies; that is, design dindicates a possibility of inconsistency and, moreover, has a strong influence that possibly changes the overall results to be carefully considered for further investigation. This influential measure can also be used as a ranking measure to prioritize designs in assessing inconsistency.

Another relevant problem is quantifying the statistical error of  $\Psi_d$  to assess how large the realized values are and to provide a reasonable threshold for deciding whether further investigations should be considered. We propose a parametric bootstrap approach as a solution to this issue. The proposed bootstrap algorithm for estimating the sampling distribution of  $\Psi_d$  is described as follows.

## Algorithm 1: Bootstrap for estimating the sampling distribution of $\Psi_d$

- Step 1. Under the multivariate random effects model (1) that assumes the global consistency (no design-by-treatment interactions) on the network, compute the REML estimates of  $(\hat{\mu}, \hat{\Sigma})$  using the all-studies dataset.
- Step 2. Resample Y<sub>1</sub><sup>(b)</sup>, Y<sub>2</sub><sup>(b)</sup>, ..., Y<sub>n</sub><sup>(b)</sup> from the estimated distribution of (1) with the parameters substituted with (μ̂, Σ̂) via parametric bootstrap, B times (b = 1,2,...,B).
  Step 3. Compute the average studentized residual Ψ<sub>d</sub><sup>(b)</sup> for the bth bootstrap sample Y<sub>1</sub><sup>(b)</sup>, Y<sub>2</sub><sup>(b)</sup>, ..., Y<sub>n</sub><sup>(b)</sup>. Also, replicate this process for all B bootstrap samples and calculate Ψ<sub>d</sub><sup>(1)</sup>, Ψ<sub>d</sub><sup>(2)</sup>, ..., Ψ<sub>d</sub><sup>(B)</sup>.

We can then estimate the sampling distribution of  $\Psi_d$  by the bootstrap distribution of  $\Psi_d^{(1)}, \Psi_d^{(2)}, ..., \Psi_d^{(B)}$  under the consistency assumption. Comparing the realized value of  $\Psi_d$  and the bootstrap distribution, we can quantitatively evaluate how the actual dataset diverges from the overall results when the consistency assumption is fulfilled. In common sense, we consider the corresponding design influential if the realized value of  $\Psi_d$  exceeds a certain quantile of the bootstrap distribution (e.g., the upper 5% quantile) <sup>18,21</sup>. In the present work, we propose a convenient measure, the *O*-value, which can be used to quantify the extremeness of the realized value in the bootstrap distribution intuitively:

$$0 = \frac{1}{B} \sum_{b=1}^{B} I\left(\Psi_d \le \Psi_d^{(b)}\right)$$

where  $I(\cdot)$  is an indicator function. A small O-value indicates that the realized value is

extreme under the consistency assumption and that the corresponding design is possibly influential. The threshold can be set arbitrarily (e.g., 5%), and we can screen individual designs in the same sense with the conventional regression diagnostics using this summary measure <sup>21</sup>. Because a certain number of designs should be evaluated in a network meta-analysis, the *O*-value is a useful measure for interpreting the overall results intuitively and immediately. Also, in prioritizing the designs on the basis of the influential measure, the *O*-values can be used as a ranking measure. The *O*-values can be similarly defined for the other influence measures proposed in the following sections.

#### 3.2 Difference-in-fit measure

Another statistical measure widely used in conventional influential diagnostics is the difference-in-fit (DFFITS) measure <sup>17,21</sup>. The DFFITS quantifies the discrepancy between the overall estimate based on all subjects and that based on a leave-one-out analysis, which is defined by the change-in-estimate standardized by a variation measure. In the inconsistency evaluation case, we consider the influence of a set of studies with the same design; that is, we propose the DFFITS measure defined by the leave-one-design-out analysis.

For the multivariate random-effect model (1), we focus on the overall estimate of  $\mu$  and propose to adopt a multivariate version of DFFITS (here named MDFFITS) as follows:

$$\text{MDFFITS}_{d} = \frac{1}{p_{d}} \left( \widehat{\boldsymbol{\mu}} - \widehat{\boldsymbol{\mu}}^{(-T_{d})} \right)^{T} \widehat{V} \left[ \widehat{\boldsymbol{\mu}}^{(-T_{d})} \right]^{-1} \left( \widehat{\boldsymbol{\mu}} - \widehat{\boldsymbol{\mu}}^{(-T_{d})} \right)$$

where  $p_d$  is the number of treatment comparisons for design d. Note that the reference treatment should also be set to one of the involved treatment arms in the design d to avoid computational irregularities and should be switched if the reference treatment is not

involved. MDFFITS quantifies how the overall estimate of  $\mu$  is changed by the leaveone-design-out analysis, which is standardized by the variance estimate of  $\hat{\mu}^{(-T_d)}$  and the number of treatment comparisons. If MDFFITS becomes large, the corresponding design *d* strongly influences the overall estimates, suggesting its design-by-treatment interaction. To quantify the statistical error, we can also adopt the parametric bootstrap approach.

### Algorithm 2: Bootstrap for estimating the sampling distribution of MDFFITS<sub>d</sub>

- Step 1. Perform Steps 1–2 in Algorithm 1 and generate the bootstrap samples  $Y_1^{(b)}, Y_2^{(b)}, ..., Y_n^{(b)}$  (b = 1, 2, ..., B).
- Step 2. Compute the DFFITS statistic MDFFITS<sub>d</sub><sup>(b)</sup> for the *b* th bootstrap sample  $Y_1^{(b)}, Y_2^{(b)}, ..., Y_n^{(b)}$ . Also, replicate this process for all *B* bootstrap samples and calculate MDFFITS<sub>d</sub><sup>(1)</sup>, ..., MDFFITS<sub>d</sub><sup>(B)</sup>.

We can then obtain the bootstrap distribution of  $MDFFITS_d$  and provide the *O*-value comparing the realized value and the bootstrap distribution. The ranking based on the *O*-values can be used in prioritizing the study designs, and the realized values can be useful referential measures for considering further investigations.

#### 3.3 Relative changes in heterogeneity statistics

The between-studies heterogeneity reflects the discordance of effect sizes in individual studies. If a strong design-by-treatment interaction exists on the network, a set of studies have enormously different effect sizes compared with the others and the heterogeneity statistics would indicate large between-studies heterogeneity in general. In this sense, the concept of heterogeneity involves that of inconsistency <sup>7</sup>. In particular, if there is a strong

design-by-treatment interaction that warrants particular attention, the heterogeneity statistics would change markedly. Thus, the relative changes of heterogeneity statistics through the leave-one-design-out analysis will be effective measures for assessing the design-by-treatment interaction. A similar approach has been adopted in outlier analyses for various meta-analysis methods <sup>17,18,20</sup>.

First, we consider the heterogeneity variance  $\tau^2$  on the covariance matrix of the random-effects distribution. A relative change measure of the  $\tau^2$  estimate is defined as the variance ratio statistic between the all-studies data and the leave-one-design-out analysis:

$$\Phi_d = \frac{\hat{\tau}^{2\,(-T_d)}}{\hat{\tau}^2}$$

where  $\hat{\tau}^{2} (-T_d)$  is the REML estimator of  $\tau^2$  from the leave-one-design-out analysis. Parameter  $\Phi_d$  quantifies the impact of design d on the size of the estimate for betweenstudies variance  $\tau^2$ . When  $\Phi_d$  is less than 1, the heterogeneity in the network decreases after design d is excluded, suggesting that design d could contribute to the betweenstudies heterogeneity on the network (i.e., design d could have a design-by-treatment interaction). In particular, a large change of  $\Phi_d$  can indicate a strong design-bytreatment interaction. Conversely, when  $\Phi_d$  is greater than 1, the heterogeneity increases after exclusion. This scenario would generally be an irregular phenomenon, and would not usually be related to design-by-treatment interactions.

Second, we consider the  $I^2$  statistic. The  $I^2$  statistic was originally proposed by Higgins and Thomson <sup>22</sup> for conventional pairwise meta-analysis and was generalized to the multivariate meta-analysis by Jackson et al. <sup>23</sup>. This measure has also been widely used in numerous systematic reviews as an effective heterogeneity assessment tool involving network meta-analysis <sup>2</sup>. The  $I^2$  statistic for multivariate meta-analysis <sup>6</sup> has been suggested as

$$I^{2} = \max\left(0, \frac{R^{2} - 1}{R^{2}}\right), R = \det\left(\frac{V[\widehat{\boldsymbol{\mu}}_{R}]}{V[\widehat{\boldsymbol{\mu}}_{F}]}\right)^{\frac{1}{2p}}$$

where  $\hat{\mu}_F$  and  $\hat{\mu}_R$  are the common-effects and grand mean estimators for the fixedeffects model and the random-effects model, respectively; the fixed-effect model corresponds to the model (1) constrained that  $\tau^2 = 0$ . We propose an alternative influential measure defined as a relative change measure of the  $I^2$  statistic between the all-studies data and the leave-one-design-out analyses:

$$\Xi_d = \frac{I^{2(-T_d)}}{I^2}$$

where  $I^{2(-T_d)}$  is the  $I^2$  statistic for the leave-one-design-out analysis. The interpretation is the same as that of  $\Phi_d$ . When  $\Xi_d$  is less than 1, the heterogeneity in the network decreases after design d is excluded, suggesting that design d could have a design-by-treatment interaction; in particular, a large change of  $\Xi_d$  can indicate a strong design-by-treatment interaction. Note that Jackson et al. <sup>23</sup> provided another definition of the  $I^2$  statistic using the  $H^2$  statistic, and the influential measure  $\Xi_d$  can be defined by the alternative definition of  $I^2$  similarly.

To quantify the statistical error, we can apply the parametric bootstrap approach.

# Algorithm 3: Bootstrap for estimating the sampling distribution of $\Phi_d$ and $\Xi_d$

- Step 1. Perform Steps 1–2 in Algorithm 1 and generate bootstrap samples  $Y_1^{(b)}, Y_2^{(b)}, \dots, Y_n^{(b)}$   $(b = 1, 2, \dots, B)$ .
- Step 2. Compute the  $\Phi_d$  and  $\Xi_d$  statistics,  $\Phi_d^{(b)}$  and  $\Xi_d^{(b)}$ , for the *b* th bootstrap sample  $Y_1^{(b)}, Y_2^{(b)}, \dots, Y_n^{(b)}$ . Also, replicate this process for all *B* bootstrap samples and calculate  $\Phi_d^{(1)}, \dots, \Phi_d^{(B)}$  and  $\Xi_d^{(1)}, \dots, \Xi_d^{(B)}$ .

We can the obtain the bootstrap distributions of  $\Phi_d$  and  $\Xi_d$  and can provide the *O*-values comparing the realized values with the bootstrap distributions. We can also create ranking lists based on the *O*-values for prioritizing the study designs, and the *O*-values can be used as referential measures for further investigations.

#### 4. Alternative testing-based approach

In Section 3, we presented influence diagnostic approaches for evaluations of design-bytreatment interactions based on the leave-one-design-out analysis. A similar approach based on statistical testing using the leave-one-design-out analysis is also straightforwardly considered. Krahn et al. <sup>7</sup> discussed a simple Wald statistic under a fixed-effect model that assesses a concordance of the common effects parameters between a set of studies with design *d* and other studies. Their method can be extended to the random-effects model (1). Denoting  $\mu^{(T_d)}$  and  $\mu^{(-T_d)}$  as the grand mean vectors of the two subsets, we can assess their possible discordance by statistical testing. The testing problem is formulated as

$$H_0: \boldsymbol{\mu}^{(T_d)} - \boldsymbol{\mu}^{(-T_d)} = \mathbf{0} \text{ v. s. } H_1: \boldsymbol{\mu}^{(T_d)} - \boldsymbol{\mu}^{(-T_d)} \neq \mathbf{0}$$

A Wald statistic for assessing the null hypothesis  $H_0$  is given as

$$W_d = \left(\widehat{\boldsymbol{\mu}}^{(T_d)} - \widehat{\boldsymbol{\mu}}^{(-T_d)}\right)^T \widehat{V}^{-1} \left(\widehat{\boldsymbol{\mu}}^{(T_d)} - \widehat{\boldsymbol{\mu}}^{(-T_d)}\right)$$

where the covariance matrix estimate  $\hat{V} = \hat{V}[\hat{\mu}^{(T_d)} - \hat{\mu}^{(-T_d)}] = \sum_{i \in (T_d)} \widehat{W}_i^{(T_d)} + \sum_{i \in (-T_d)} \widehat{W}_i^{(-T_d)}$ . The Wald statistic  $W_d$  asymptotically follows a  $\chi^2$ -distribution with  $p_d$  degrees of freedom under the null hypothesis. When the null hypothesis is rejected, the discordance of effect sizes (i.e., the inconsistency by design d) is suggested. Notably, the results of this Wald test accord to those of the inconsistency tests of sidesplitting <sup>5,24,25</sup> if the corresponding design d is a two-arm design. Although the sidesplitting focuses on

specific treatment pairs, our proposed testing approach focuses on specific designs.

From a mathematical perspective, the large sample approximation using a  $\chi^2$ -distribution might be violated in the case of a limited number of studies <sup>26</sup>. Even in such cases, the parametric bootstrap approach discussed in Section 3 can be used to estimate the sampling distribution of  $W_d$  and the resultant inference can be improved <sup>26</sup>. The bootstrap algorithm is given as follows:

# Algorithm 4: Bootstrap for estimating the sampling distribution of $W_d$

- Step 1. Perform Steps 1–2 in Algorithm 1 and generate the bootstrap samples  $Y_1^{(b)}, Y_2^{(b)}, \dots, Y_n^{(b)}$   $(b = 1, 2, \dots, B)$ .
- Step 2. Compute the Wald statistics,  $W_d^{(b)}$ , for the *b* th bootstrap sample  $Y_1^{(b)}, Y_2^{(b)}, \dots, Y_n^{(b)}$ . Also, replicate this process for all *B* bootstrap samples and calculate  $W_d^{(1)}, \dots, W_d^{(B)}$ .

We can provide the bootstrap *P*-value using the empirical distribution of  $W_d^{(1)}$ , ...,  $W_d^{(B)}$  as the reference distribution instead of the  $\chi^2$ -distribution. Notably, this testing approach also suffers from the limitation of statistical power and instability of  $\tau^2$  estimation in the subset  $T_d$ , which involves a few studies in many cases; however, in practice, it might be an alternative useful option familiar to many practitioners.

#### 5. Application

To illustrate the effectiveness of the proposed methods, we applied them to a network meta-analysis of antihypertensive drugs by Sciarretta et al. <sup>12</sup>. The network meta-analysis included 26 randomized controlled trials comparing seven drug classes [ $\alpha$ -blocker (AB), angiotensin-converting enzyme inhibitor (ACE), angiotensin II receptor blocker (ARB),

β-blocker (BB), calcium channel blocker (CCB), conventional treatment (CT), and diuretic (DD)] and placebo. The outcome was the incidence of heart failure. The network diagram of this study is presented in Figure 1, and the 26 studies and their designs are summarized in Table 1. The network included 18 designs, two of which were three-arm trials (STOP-2 and ALLHAT2002); the others were all two-arm trials. Note that the Jikei Heart Study included in the design of ARB vs CT was found to include falsified data, and the main result paper was retracted <sup>27</sup>; the active treatment was categorized in ARB, and its efficacy was reported to be remarkably large compared with that of CT. Thus, in this network, the efficacy of ARB could be overestimated because of this extreme data. Given this fact, a naïve hypothesis is that the design of ARB vs CT could raise a design-by-treatment interaction on this network.

The primary results of this network meta-analysis using the REML method are shown in Figure 2(a). The odds-ratio (OR) was adopted for the effect measure, and the reference group was set to placebo. For the between-study heterogeneity,  $\hat{\tau}$  was 0.099 and  $I^2$  was 56.9%. Also, the *P*-value of the global inconsistency test was 0.459; significant inconsistency was not detected, possibly because of the low power.

We used the four influence diagnostic methods for this network meta-analysis. Note the design of AB vs DD was excluded in the analyses because AB was included in only one study (ALLHAT2000) and was isolated in the network. In the bootstrap analyses, we performed 5,000 resamplings consistently and we formally regarded the designs with O< 0.05 as influential designs. The results are presented in Figure 3. The averaged studentized residuals and their *O*-values for 17 designs are presented in Figure 3(a) and (b); the design IDs are presented in Table 1. DD vs Placebo (design 17), ARB vs CT (design 11), and ACE vs DD (design 7) had the largest averaged studentized residuals, and the *O*-values of the first two designs were less than 0.05. ARB vs CT included the Jikei Heart Study and E-COST, and DD vs Placebo included HYVET. MDFFITS gave results similar to those of the averaged studentized residuals for the *O*-values [Figure 3(c) and (d)]. Although the rankings of MDFFITS were slightly different, the *O*-values of ARB vs CT and DD vs Placebo were less than 0.05. In addition, the results obtained by the analyses using  $\Phi_d$  and  $\Xi_d$  are presented in Figure 3(e)–(h). Both  $\Phi_d$  and  $\Xi_d$  were less than 1 for seven designs (DD vs Placebo, ARB vs Placebo, ARB vs CT, BB vs CCB, CCB vs Placebo, ACE vs DD, and ARB vs BB). Unlike the former two methods, only DD vs Placebo showed O < 0.05. Also, these two measures' overall rankings based on heterogeneity statistics were similar.

Table 2 shows the results of the testing approach by leave-one-design-out analysis. The *P*-values were computed using the bootstrap method with 5,000 resamplings, and the significant level was set to 0.05. The statistical tests detected only ARB vs CT as a significant design (the bootstrap *P*-value was less than 0.05). The pooled OR estimates and 95% confidence intervals (CIs) were 1.501 (0.991, 2.272) for studies with the design ARB vs CT and 0.911 (0.744, 1.117) for the other studies.

In summary, the design DD vs Placebo was detected by all four influence diagnostic methods. This study included the HYVET study, which is an effectiveness trial of DD for patients 80 years of age or older; the patient background in this study is especially different from that in the other studies. Also, this study was terminated at the interim analysis because of the efficacy of DD <sup>28</sup> and the effect of DD might be overestimated (OR: 0.375, 95% CI: 0.228, 0.615). Also, ARB vs CT was detected by the two influence diagnostic methods using averaged studentized residual and MDFFITS, and the testing approach. This design included the Jikei Heart Study and the E-COST trial. As expected, the Jikei Heart Study had an extreme profile on the network, and these proposed methods detected the corresponding design as an influential one that could change the overall

results.

To assess the potential influence of the two detected study designs on the overall estimates, we conducted a sensitivity analysis that excluded the corresponding three studies: Jikei Heart Study, E-COST, and HYVET. The pooling results are presented in Figure 2(b). Overall, the sizes of the comparative OR estimates increased after the exclusion, except for that for CT. In particular, the efficacy of ARB decreased and the rankings of ARB and CT were reversed. The results imply that the treatment effects of the investigational drugs, except those of CT, might be overestimated in the original network meta-analysis. Also, the heterogeneity got lower: the  $\tau$  estimate changed from 0.099 to 0.054, and  $I^2$  changed from 56.9% to 31.7%. Furthermore, the *P*-value of the global inconsistency test increased from 0.459 to 0.911. In the original report of this network meta-analysis <sup>12</sup>, the inconsistency was reported to be low; however, these results would provide additional insights and the overall results should be interpreted more carefully.

#### 6. Discussion

In network meta-analysis, the evaluation of inconsistency is a critical issue to ensure the validity of evidence synthesis. Existing methods are mainly founded on statistical testing for local or global characteristics on the network <sup>3-7</sup>, and the results are provided whether significant or not. The primary purpose of these analyses is to explore possible sources of biases or irregular issues on the network and prioritize the designs that have interactions with the treatments. The proposed statistical methods quantify how the overall results change when a specific set of studies is excluded, and these results will provide new insights to enable assessments of the design-by-treatment interactions. In particular, to

prioritize study designs for further investigations, these new methods will be useful alternatives to existing inconsistency evaluation tools.

Lu et al. <sup>29</sup> proposed a similar idea of using studentized residuals for assessing local inconsistency; however, they did not adopt the leave-one-design-out scheme. In general, the naïve studentized residual can involve "optimism" because it is defined by the overall estimates using the information of the target cases themselves, as is known in conventional regression diagnosis <sup>21</sup>. The new methods address this substantial problem and enable more sophisticated evaluations for statistical errors via a bootstrapping approach.

We also proposed a convenient summary measure: the *O*-value. The quantitative information of influential measures is dropped in the *O*-value; however, the *O*-value can be conveniently used to assess the impact of designs such as the *P*-value of statistical testing. The proposed influential measures and *O*-values will be effectively applicable for the prioritizations. However, the results should be interpreted using both measures simultaneously. In particular, the influential measures provide relevant quantitative information concerning the degrees of influences.

In addition, our methods enable direct evaluations of the influences of designs. The global inconsistency test uses whole statistical information on the network; however, the design-by-treatment interaction model does not enable easy interpretation of where the inconsistency exists. Also, few proposed methods can evaluate local inconsistency while addressing the influences of multi-arm studies <sup>30,31</sup>. Our new methods focus on assessing the influences of designs directly, and the results indicate which designs influence consistency on the network. Also, the global inconsistency test rarely provides significant results, whereas our methods detect potentially relevant local information effectively, as

demonstrated in Section 5. These results will provide alternative new insights that were not provided by existing methods.

In conclusion, our proposed methods are expected to provide new insights in inconsistency evaluations of network meta-analysis. In addition to the current standard testing-based approaches, these methods can be used as alternative effective approaches to locating inconsistency on a network.

#### Acknowledgements

This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Grant numbers: JP23K24811, JP22H03554, JP22K19688, and JP23K11931).

#### References

- 1. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. *Res Synth Methods*. 2012;3(2):80-97.
- 2. Nikolakopoulou A, White IR, Salanti G. Network meta-analysis. In: Schmid CH, Stijnen T, White IR, eds. *Handbook of Meta-Analysis*. CRC Press; 2021:187-217.
- Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res Synth Methods*. 2012;3(2):98-110.
- Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. *J Clin Epidemiol.* 1997;50(6):683-691.
- 5. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment

comparison meta-analysis. Stat Med. 2010;29(7-8):932-944.

- Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. *Stat Med.* 2014;33(21):3639-3654.
- Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analysis. *BMC Med Res Methodol*. 2013;13:35.
- 8. Efthimiou O, Debray TP, van Valkenhoef G, et al. GetReal in network meta-analysis: a review of the methodology. *Res Synth Methods*. 2016;7(3):236-63.
- Veroniki AA, Mavridis D, Higgins JP, Salanti G. Characteristics of a loop of evidence that affect detection and estimation of inconsistency: a simulation study. *BMC Med Res Methodol*. 2014;14:106.
- Song F, Clark A, Bachmann MO, Maas J. Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons. *BMC Med Res Methodol*. 2012;12:138.
- White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. *Res Synth Methods*. 2012;3(2):111-125.
- Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. *Arch Intern Med.* 2011;171(5):384-94.
- 13. Noma H. Within-study covariance estimators for network meta-analysis with contrast-based approach. *Jpn J Biometrics*. 2024;44(2):119-126.
- 14. Noma H, Hamura Y, Gosho M, Furukawa TA. Kenward-Roger-type corrections for inference methods of network meta-analysis and meta-regression. *Res Synth Methods*.

2023;14(5):731-741.

- Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. *Stat Med.* 1996;15(24):2733-2749.
- Jackson D, Riley R, White IR. Multivariate meta-analysis: potential and promise. *Stat* Med. 2011;30(20):2481-98.
- Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. *Res* Synth Methods. 2010;1(2):112-25.
- Noma H, Gosho M, Ishii R, Oba K, Furukawa TA. Outlier detection and influence diagnostics in network meta-analysis. *Res Synth Methods*. 2020;11(6):891-902.
- Matsushima Y, Noma H, Yamada T, Furukawa TA. Influence diagnostics and outlier detection for meta-analysis of diagnostic test accuracy. *Res Synth Methods*. 2020;11(2):237-247.
- 20. Negeri ZF, Beyene J. Statistical methods for detecting outlying and influential studies in meta-analysis of diagnostic test accuracy studies. *Stat Methods Med Res.* 2020;29(4):1227-1242.
- 21. Belsley DA, Kuh E, Welsch RE. Regression Diagnostics. Wiley; 1980.
- Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* 2002;21(11):1539-1558.
- 23. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. *Stat Med.* 2012;31(29):3805-3820.
- 24. Noma H, Tanaka S, Matsui S, Cipriani A, Furukawa TA. Quantifying indirect evidence in network meta-analysis. *Stat Med.* 2017;36(6):917-927.
- Noma H. Sidesplitting using network meta-regression. Jpn J Biometrics. 2024;44(2):107-118.
- 26. Noma H, Nagashima K, Maruo K, Gosho M, Furukawa TA. Bartlett-type corrections

and bootstrap adjustments of likelihood-based inference methods for network metaanalysis. *Stat Med.* 2018;37(7):1178-1190.

- 27. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study (retracted). *Lancet*. 2007;369(9571):1431-1439.
- Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med.* 2008;358(18):1887-98.
- 29. Lu G, Welton NJ, Higgins JP, White IR, Ades AE. Linear inference for mixed treatment comparison meta-analysis: A two-stage approach. *Res Synth Methods*. 2011;2(1):43-60.
- Seitidis G, Nikolakopoulos S, Ntzoufras I, Mavridis D. Inconsistency identification in network meta-analysis via stochastic search variable selection. *Stat Med.* 2023;42(26):4850-4866.
- Turner RM, Band T, Morris TP, et al. A new approach to evaluating loop inconsistency in network meta-analysis. *Stat Med.* 2023;42(27):4917-4930.

Design ID	Design	Trial	Drug 1	d/n	Drug 2	d/n	Drug 3	d/n
1	ACE vs ARB	ONTARGET	ACE	514/8576	ARB	537/8542	_	
2	ACE vs BB	UKPDS	ACE	12/400	BB	9/358	_	
3	ACE vs CCB	ABCD	ACE	5/235	CCB	6/235	_	—
4	ACE vs CCB vs CT	STOP-2	ACE	149/2205	CCB	186/2196	CT	177/2213
5	ACE vs CCB vs DD	ALLHAT2002	ACE	612/9054	CCB	706/9048	DD	870/15255
6	ACE vs CT	CAPPP	ACE	75/5492	CT	66/5493	—	—
7	ACE vs DD	ANBP2	ACE	69/3044	DD	78/3039	—	—
8	ACE vs Placebo	HOPE	ACE	417/4645	Placebo	535/4652	—	—
9	ARB vs BB	LIFE	ARB	153/4605	BB	161/4588	_	—
10	ARB vs CCB	VALUE	ARB	354/7649	CCB	400/7596	_	—
11	ARB vs CT	E-COST	ARB	35/1053	CT	41/995	_	—
11	ARB vs CT	Jikei Heart Study	ARB	19/1541	CT	36/1540	—	
12	ARB vs Placebo	RENRAL	ARB	89/751	Placebo	127/762	—	
12	ARB vs Placebo	TRANSEND	ARB	134/2954	Placebo	129/2972	—	
13	BB vs CCB	ASCOT-BPLA	BB	159/9618	CCB	134/9639	—	
14	CCB vs CT	NORDIL	CCB	63/5410	CT	53/5471	_	—
14	CCB vs CT	CONVINCE	CCB	126/8179	CT	100/8297	—	—
15	CCB vs DD	VHAS	CCB	2/707	DD	0/707	—	—
15	CCB vs DD	NICS-EH	CCB	0/204	DD	3/210	—	—
15	CCB vs DD	INSIGHT	CCB	26/3157	DD	12/3164	—	—
15	CCB vs DD	SHELL	CCB	23/942	DD	19/940	—	—
16	CCB vs Placebo	Syst-Eur	CCB	37/2398	Placebo	49/2297	—	—
16	CCB vs Placebo	Syst-China	CCB	4/1253	Placebo	8/1141	_	—
16	CCB vs Placebo	FEVER	CCB	18/4841	Placebo	27/4870	_	—
17	DD vs Placebo	HYVET	DD	22/1933	Placebo	57/1912	_	
18	AB vs DD	ALLHAT2000	AB	491/9067	DD	420/15268	_	—

 Table 1. Summary of the network meta-analysis dataset of Sciarretta et al. <sup>12</sup>

Abbreviations: AB, α-blocker; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, β-blocker; CCB, calcium channel blocker; CT, conventional treatment; DD, diuretic; d/n, number of incidences of heart failure/number of participants.

Design ID	Design	W <sub>d</sub>	<i>P</i> -value	Treatment	Reference treatment	$\exp(\hat{\mu}^{(T_d)})^*$	$\exp(\hat{\mu}^{(-T_d)})^*$
11	ARB vs CT	4.472	0.036	CT	ARB	1.501	0.911
17	DD vs Placebo	4.216	0.052	Placebo	DD	2.669	1.534
7	ACE vs DD	3.743	0.089	DD	ACE	1.136	0.787
16	CCB vs Placebo	2.125	0.133	Placebo	CCB	1.474	1.107
14	CCB vs CT	2.306	0.148	СТ	CCB	0.797	1.010
13	BB vs CCB	2.093	0.197	CCB	BB	0.839	1.115
6	ACE vs CT	1.803	0.233	СТ	ACE	0.878	1.144
2	ACE vs BB	0.805	0.382	BB	ACE	0.834	1.265
9	ARB vs BB	0.951	0.404	BB	ARB	1.058	1.286
12	ARB vs Placebo	0.704	0.406	Placebo	ARB	1.183	1.455
8	ACE vs Placebo	0.835	0.471	Placebo	ACE	1.318	1.502
15	CCB vs DD	0.099	0.734	DD	CCB	0.656	0.721
4	ACE vs CCB vs CT	0.798	0.756	CCB	ACE	1.277	1.152
				CT	ACE	1.200	1.044
10	ARB vs CCB	0.110	0.797	CCB	ARB	1.145	1.097
1	ACE vs ARB	0.006	0.951	ARB	ACE	1.052	1.063
3	ACE vs CCB	0.001	0.971	CCB	ACE	1.205	1.181
5	ACE vs CCB vs DD	0.016	0.994	CCB	ACE	1.167	1.183
				DD	ACE	0.834	0.831
18	AB vs DD			—		—	—

Table 2. Results of the testing approach for the antihypertensive drugs network meta-analysis.

 $\hat{\mu}$  was estimated as the log odds ratio scale, and the estimate was transformed to the odds ratio scale.

Abbreviations: AB,  $\alpha$ -blocker; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB,  $\beta$ -blocker; CCB, calcium channel blocker; CT, conventional treatment; DD, diuretic.



Figure 1. Network diagram of the network meta-analysis for antihypertensive drugs. (AB, α-blocker; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, β-blocker; CCB, calcium channel blocker; CT, conventional treatment; DD, diuretic)



**Figure 2.** Pooled odds ratio estimates of antihypertensive drugs compared to placebo: (a) by all 26 studies; (b) by 23 studies after excluding Jikei Heart Study, E-COST, and HYVET. (AB, α-blocker; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, β-blocker; CCB, calcium channel blocker; CT, conventional treatment; DD, diuretic)



**Figure 3.** Influence diagnostics results to evaluate inconsistency: (a)  $\Psi_d$  (averaged studentized residual); (b) *O*-value of  $\Psi_d$ ; (c) MDFFITS<sub>d</sub>; (d) *O*-value of MDFFITS<sub>d</sub>; (e)  $\Phi_d$ ; (f) *O*-value of  $\Phi_d$ ; (g)  $\Xi_d$ ; (h) *O*-value of  $\Xi_d$ .